Onradivir
Based on 1 Customer Validation
Onradivir (ZSP1273) is an orally active antiviral agent targeting influenza A virus RNA polymerase PB2 subunit with an IC50 of 0.562 nM. Onradivir inhibits cap binding to influenza A virus RNA polymerase PB2 subunit, suppresses viral replication, reduces viral titres and RNA loads, and inhibits influenza A virus infection. Onradivir maintains high survival rates in influenza A virus-infected mice, and reduces influenza A virus titers in a murine model. Onradivir can be used for the research of influenza A virus infection.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 99.53%
- No. CAS: 2200336-20-3
- Fòrmula: C22H22F2N6O2
- Peso molecular:440.45
-
Almacenamiento:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Pureza y Documentación
- Referencias
-
Help & FAQs
-
Anti-Infection Compound Library
HY-L002
-
Cell Cycle/DNA Damage Compound Library
HY-L004
-
Antiviral Compound Library
HY-L027
-
Anti-Aging Compound Library
HY-L034
-
Orally Active Compound Library
HY-L061
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
Ver todos los productos específicos de isoformas DNA/RNA Synthesis
More
Actividad biológica
|
RNA Polymerase |
Onradivir (0.457-1000 nM; 24 h post-6-hour transfection) potently inhibits influenza A virus polymerase activity in HEK293T cells, with a mean IC50 of 0.562 nM[2].
Onradivir (0.17-10,000 nM) does not inhibit most tested human kinases at concentrations up to 10,000 nM, with only weak activity against Aurora A kinase (IC50 = 527 nM)[2].
Onradivir (0.0005-100 μM; 2-5 days) potently inhibits replication of wild-type, Oseltamivir (HY-13317)-resistant, and Baloxavir (HY-109025A)-resistant influenza A strains in MDCK cells (EC50 0.012-0.063 nM) with high selective index, and shows weak activity against HRV-1B (EC50 7.88 μM) in H1 HeLa cells[2].
Onradivir (48 h post-virus infection) potently inhibits replication of highly pathogenic avian influenza H7N9 and H5N6 viruses in MDCK cells, with IC50 values ranging from 0.245-0.777 nM[2].
Onradivir (10 μM; 3 days) does not inhibit HCV genotype 1b replicon replication or cause cytotoxicity at concentrations up to 10 μM[2].
Onradivir (0.16-40 μM; 1 min per concentration) does not significantly inhibit hERG potassium channel function in CHO cells at concentrations up to 40 μM (IC50 >40 μM)[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| Species | Dose | Route | CL | T1/2 | Vdss | AUC0-last | Cmax | Tmax | Bioavailability |
|---|---|---|---|---|---|---|---|---|---|
| Rat[2] | 3 mg/kg | i.v. | 12.9 mL/min/kg | 2.11 h | 0.508 L/kg | 3950 ng·h/mL | / | / | / |
| Rat[2] | 3 mg/kg | p.o. | / | / | / | 899 ng·h/mL | 661 ng/mL | / | 22.8 % |
| Rat[2] | 15 mg/kg | p.o. | / | / | / | 7490 ng·h/mL | 5620 ng/mL | / | / |
| Rat[2] | 75 mg/kg | p.o. | / | / | / | 77700 ng·h/mL | 17200 ng/mL | / | / |
| Dog[2] | 1 mg/kg | i.v. | 25.8 mL/min/kg | 0.457 h | 0.470 L/kg | 791 | / | / | / |
| Dog[2] | 1 mg/kg | p.o. | / | / | / | 211 ng·h/mL | 292 ng/mL | 0.458 h | 26.7 % |
| Dog[2] | 5 mg/kg | p.o. | / | / | / | 1210 ng·h/mL | 1450 ng/mL | 0.542 h | / |
| Dog[2] | 15 mg/kg | p.o. | / | / | / | 5030 ng·h/mL | 5800 ng/mL | 0.458 h | / |
Onradivir (ZSP1273) (10 mg/kg; p.o.; twice daily; 7 days) provides 100% survival when administered 4 h pre-infection, improves survival when administered 48 h post-infection, provides partial survival when administered 72 h post-infection, and extends time to death when administered 96 h post-infection in influenza A virus WSN/33 (H1N1)-infected female BALB/c mice[2].
Onradivir (ZSP1273) (30-100 mg/kg; p.o.; twice daily; 7 days) provides 100% survival at 30 mg/kg, and provides high survival with minimal deaths at 100 mg/kg, when administered starting 48 h post-infection in influenza A virus WSN/33 (H1N1)-infected female BALB/c mice[2].
Onradivir (ZSP1273) (25 mg/kg; p.o.; twice daily; 5 days) significantly reduces nasal lavage viral load and maintains stable body weight in influenza A virus/California/07/2009 (H1N1)-infected female ferrets when administered starting 4 h pre-infection[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c (female, SPF grade, 6-7 weeks old, 16-18 g, intranasal inoculation with influenza A virus WSN/33 (H1N1))[2]
-
Dosage:3 mg/kg (day 5 endpoint); 10 mg/kg (day 3 endpoint; day 5 endpoint); 30 mg/kg (day 5 endpoint)
-
Administration:p.o.; twice daily; days 1-2 (day 3 endpoint); days 1-4 (day 5 endpoint)
-
Result:Reduced lung viral titers.
Enabled mice in the 30 mg/kg group to begin regaining body weight on day 4.
Enabled mice in the 10 mg/kg group to begin regaining body weight on day 5.
-
Animal Model:BALB/c (female, SPF grade, 6-7 weeks old, 16-18 g, intranasal inoculation with influenza A virus WSN/33 (H1N1))[2]
-
Dosage:10 mg/kg
-
Administration:p.o.; twice daily; 7 consecutive days; first dose at 4 h pre-infection; first dose at 48 h post-infection; first dose at 72 h post-infection; first dose at 96 h post-infection
-
Result:Maintained a 100% survival rate through day 14 and prevented significant body weight loss when dosed at 4 h pre-infection.
Improved survival rate compared to vehicle and supported body weight recovery starting after nadir weight loss when dosed at 48 h post-infection.
Resulted in a 25% survival rate.
Chemical Information
-
No. CAS 2200336-20-3
-
Appearance Solid
-
Peso molecular 440.45
-
Fòrmula C22H22F2N6O2
-
Color Off-white to light yellow
-
SMILES
FC1=CN=C2C(C(C3=NC(N[C@@H]4[C@H](C5CCC4CC5)C(O)=O)=C(F)C(C6CC6)=N3)=NN2)=C1
-
Synonyms
ZSP1273
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvente y solubilidad
DMSO : 100 mg/mL (227.04 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 2.5 mg/mL (5.68 mM); Clear solution; Need ultrasonic
This protocol yields a clear solution of 2.5 mg/mL.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureza y Documentación
-
Ficha de datos (281 KB)
-
SDS (254 KB)
- English - EN (254 KB)
- Français - FR (254 KB)
- Deutsch - DE (254 KB)
- Norwegian - NO (254 KB)
- Español - ES (254 KB)
- Swedish - SV (254 KB)
- Italian - IT (254 KB)
- Korean - KR (254 KB)
- Portuguese - PT (254 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Li J, et al. Onradivir: a novel influenza polymerase inhibitor. Lancet Respir Med. 2025 Jul;13(7):571-573. [Content Brief]
[2]. Chen X, et al. Preclinical Study of ZSP1273, a Potent Antiviral Inhibitor of Cap Binding to the PB2 Subunit of Influenza A Polymerase. Pharmaceuticals (Basel). 2023;16(3):365. Published 2023 Feb 27. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.2704 mL | 11.3520 mL | 22.7041 mL | 56.7601 mL |
| 5 mM | 0.4541 mL | 2.2704 mL | 4.5408 mL | 11.3520 mL | |
| 10 mM | 0.2270 mL | 1.1352 mL | 2.2704 mL | 5.6760 mL | |
| 15 mM | 0.1514 mL | 0.7568 mL | 1.5136 mL | 3.7840 mL | |
| 20 mM | 0.1135 mL | 0.5676 mL | 1.1352 mL | 2.8380 mL | |
| 25 mM | 0.0908 mL | 0.4541 mL | 0.9082 mL | 2.2704 mL | |
| 30 mM | 0.0757 mL | 0.3784 mL | 0.7568 mL | 1.8920 mL | |
| 40 mM | 0.0568 mL | 0.2838 mL | 0.5676 mL | 1.4190 mL | |
| 50 mM | 0.0454 mL | 0.2270 mL | 0.4541 mL | 1.1352 mL | |
| 60 mM | 0.0378 mL | 0.1892 mL | 0.3784 mL | 0.9460 mL | |
| 80 mM | 0.0284 mL | 0.1419 mL | 0.2838 mL | 0.7095 mL | |
| 100 mM | 0.0227 mL | 0.1135 mL | 0.2270 mL | 0.5676 mL |
Powered by Bioz